Biotech Values

[DewDiligence]

…I was as pessimistic as anyone about the amount of competition - since I assumed the non-subs biosimilars hit the market well before MNTAs generic and take market that cannot be easily recovered just because it is fully subs.

I don’t get your point. A single substitutable FoB is guaranteed to make good money as long as the corresponding branded drug continues to sell well.